AG
XLRN

Aperio Group’s Acceleron Pharma XLRN Stock Holding History

Aperio Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.75M Buy
13,668
+2,064
+18% +$242K 0.01% 1306
2020
Q3 		$1.31M Sell
11,604
-459
-4% -$45.7K ﹤0.01% 1314
2020
Q2 		$1.15M Buy
12,063
+2,927
+32% +$282K ﹤0.01% 1350
2020
Q1 		$821K Buy
9,136
+2,664
+41% +$207K ﹤0.01% 1388
2019
Q4 		$343K Sell
6,472
-59
-0.9% -$2.69K ﹤0.01% 2001
2019
Q3 		$258K Buy
6,531
+1,906
+41% +$82.7K ﹤0.01% 2082
2019
Q2 		$190K Buy
+4,625
New +$191K ﹤0.01% 2193

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aperio Group's XLRN Position: Q4 2020 in Review

Aperio Group increased its Acceleron Pharma (XLRN) stake by 18% in Q4 2020, buying an estimated $242K and bringing the position to 13,668 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #1306.

Aperio Group first reported a position in XLRN in Q2 2019 and has held it in 7 quarters since. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

  • Aperio Group held 13,668 shares of Acceleron Pharma worth $1.75M as of Q4 2020.
  • Aperio Group bought 2,064 Acceleron Pharma shares in Q4 2020, an estimated $242K.
  • Acceleron Pharma made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1306 holding.
  • Aperio Group first reported a position in Acceleron Pharma in Q2 2019 and has held it in 7 quarters since.
  • 253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.